Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.

NCT: NCT03273712

Locations: University of Iowa Hospitals and Clinics

Link: https://clinicaltrials.gov/ct2/show/NCT03273712?recrs=ad&cond=Neuroblastoma&locn=University+of+Iowa&cntry=US&age=0&draw=2&rank=1